Testing sintilimab and linperlisib for NK/T-cell lymphoma
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extranodal NK/T-cell lymphoma (a type of lymphoma).
- Your cancer has returned or did not get better after at least one prior treatment that included asparaginase (a chemotherapy drug).
- You are 18 years or older.
- You are willing and able to give informed consent.
- You have a good performance status (able to care for yourself and get around).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This trial tests a combination of three medicines (sintilimab, chidamide, and azacitidine) to treat a rare blood cancer called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination can control the cancer better than traditional approaches.
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests a combination of three drugs—selinexor, an anti-PD-1 antibody (immune therapy), and golidocitinib—for people with NK/T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Extranodal Natural Killer T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.